

1/13

## **BETANAL QUATTRO**

Version 2 / NZ
102000000613

Revision Date: 29.07.2022
Print Date: 29.07.2022

# SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier

Trade name BETANAL QUATTRO

Product code (UVP) 06367933

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use Herbicide EPA-Nr. HSR100882

1.3 Details of the supplier of the safety data sheet

**Supplier** Bayer New Zealand Limited

Crop Science Division B:HIVE Building 74 Taharoto Rd Smales Farm Takapuna Auckland, 0622 New Zealand

**Telephone** 0800 428 246

**Telefax** (09) 441 8645

1.4 Emergency telephone no.

**Emergency Number** 0800 734 607 (24hr)

Global Incident Response

Hotline (24h)

+1 (760) 476-3964 (Company 3E for Bayer AG, Crop Science Division)

## **SECTION 2: HAZARDS IDENTIFICATION**

#### 2.1 Classification of the substance or mixture

Classified as hazardous according to the criteria in the Hazardous Substances (Minimum Degrees of Hazard) Notice 2020 as amended

Acute Tox. 4

H332 Harmful if inhaled.

STOT RE 2

H373 May cause damage to organs through prolonged or repeated exposure.

Aquatic Chronic 2

H411 Toxic to aquatic life with long lasting effects.



2/13

## **BETANAL QUATTRO**

Version 2 / NZ
102000000613

Revision Date: 29.07.2022
Print Date: 29.07.2022

Hazardous to soil organisms

H421 Very toxic to the soil environment.H433 Harmful to terrestrial vertebrates.

#### 2.2 Label elements

# Labelling in accordance with the Hazardous Substances (Safety Data Sheets) Notice 2020 as amended

Hazard label for supply/use required.







## Signal word: Warning Hazard statements

H332 Harmful if inhaled.

H373 May cause damage to organs through prolonged or repeated exposure.

H411 Toxic to aquatic life with long lasting effects.

H421 Very toxic to the soil environment. H433 Harmful to terrestrial vertebrates.

#### **Precautionary statements**

P102 Keep out of reach of children.

P260 Do not breathe dust/fume/gas/mist/vapours/spray.

P391 Collect spillage.

P314 Get medical advice/ attention if you feel unwell.

P501 Dispose of contents/container in accordance with local regulation.

#### 2.3 Other hazards

No additional hazards known beside those mentioned.

#### SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

#### 3.2 Mixtures

#### **Chemical nature**

Suspo-emulsion (SE)

5.5% Phenmedipham (60 g/l), 5.5% Desmedipham (60 g/l), 5.5% Ethofumesate (60 g/l), 18.3% Metamitron (200 g/l)

#### **Hazardous components**

Chemical name	CAS-No.	Conc. [%]
Phenmedipham	13684-63-4	5.50
Desmedipham	13684-56-5	5.50
Ethofumesate	26225-79-6	5.50
Metamitron	41394-05-2	18.30
Ammonium distyrylphenyl ether sulphate	59891-11-1	>= 1.0 - < 3.0
Ethoxylated alcohols (C12-15)	68131-39-5	>= 0.1 - < 1
1,2-Benzisothiazol-3(2H)-one	2634-33-5	>= 0.005 - < 0.05



## **BETANAL QUATTRO**

3/13 Version 2/NZ Revision Date: 29.07.2022 102000000613 Print Date: 29.07.2022

#### **Further information**

1,2-Benzisothiazol- 3(2H)-one	2634-33-5	M-Factor: 10 (acute)
----------------------------------	-----------	----------------------

#### **SECTION 4: FIRST AID MEASURES**

## 4.1 Description of first aid measures

General advice Move out of dangerous area. Place and transport victim in stable

position (lying sideways). Remove contaminated clothing immediately

and dispose of safely.

Inhalation Move to fresh air. Keep patient warm and at rest. Call a physician or

poison control center immediately.

Wash off thoroughly with plenty of soap and water, if available with Skin contact

polyethyleneglycol 400, subsequently rinse with water. Call a physician

or poison control center immediately.

Rinse immediately with plenty of water, also under the evelids, for at Eye contact

least 15 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing eye. Call a physician or poison control

center immediately.

Ingestion Rinse mouth. Do NOT induce vomiting. Call a physician or poison

control center immediately.

#### 4.2 Most important symptoms and effects, both acute and delayed

**Symptoms** Tiredness, Headache, Trembling, lethargy, Dyspnoea, ataxia

#### 4.3 Indication of any immediate medical attention and special treatment needed

**Risks** This product, although being a carbamate, is NOT a cholinesterase

inhibitor.

**Treatment** Treat symptomatically. In case of ingestion gastric lavage should be

> considered in cases of significant ingestions only within the first 2 hours. However, the application of activated charcoal and sodium sulphate is always advisable. There is no specific antidote. Forced

alkaline diuresis and hemodialysis may be considered.

Contact the National Poisons and Hazardous Chemicals Information center in Dunedin, PO Box 913, Dunedin. Phone 0800 POISON (0800 764 766).

## **SECTION 5: FIREFIGHTING MEASURES**

#### 5.1 Extinguishing media

Suitable Water spray, Carbon dioxide (CO2), Foam, Sand

Unsuitable High volume water jet



4/13

## **BETANAL QUATTRO**

Version 2 / NZ
102000000613

Revision Date: 29.07.2022
Print Date: 29.07.2022

5.2 Special hazards arising from the substance or

mixture

In the event of fire the following may be released:, Hydrogen cyanide (hydrocyanic acid), Carbon monoxide (CO), Sulphur oxides, Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment for firefighters

In the event of fire and/or explosion do not breathe fumes. Wear self-contained breathing apparatus and protective suit.

**Further information** 

Contain the spread of the fire-fighting media. Do not allow run-off from fire fighting to enter drains or water courses.

#### **SECTION 6: ACCIDENTAL RELEASE MEASURES**

#### 6.1 Personal precautions, protective equipment and emergency procedures

**Precautions** Avoid contact with spilled product or contaminated surfaces. Use

personal protective equipment.

6.2 Environmental

precautions

Do not allow to get into surface water, drains and ground water.

#### 6.3 Methods and materials for containment and cleaning up

Methods for cleaning up Soak up with inert absorbent material (e.g. sand, silica gel, acid

binder, universal binder, sawdust). Clean contaminated floors and objects thoroughly, observing environmental regulations. Collect and transfer the product into a properly labelled and tightly closed

container.

**Additional advice** Check also for any local site procedures.

6.4 Reference to other

sections

Information regarding safe handling, see section 7.

Information regarding personal protective equipment, see section 8.

Information regarding waste disposal, see section 13.

#### **SECTION 7: HANDLING AND STORAGE**

#### 7.1 Precautions for safe handling

**Advice on safe handling** Use only in area provided with appropriate exhaust ventilation.

Advice on protection against fire and explosion

No special precautions required.

Hygiene measures Avoid contact with skin, eyes and clothing. Keep working clothes

separately. Wash hands before breaks and immediately after handling the product. Remove soiled clothing immediately and clean thoroughly

before using again.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Store in original container. Store in a place accessible by authorized persons only. Keep containers tightly closed in a dry, cool and well-ventilated place. Protect from frost. Keep away from direct sunlight.

Advice on common storage Keep away from food, drink and animal feedingstuffs.



5/13

## **BETANAL QUATTRO**

Version 2 / NZ
102000000613

Revision Date: 29.07.2022
Print Date: 29.07.2022

Suitable materials HDPE (high density polyethylene)7.3 Specific end use(s) Refer to the label and/or leaflet.

#### SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

#### 8.1 Control parameters

Components	CAS-No.	Control parameters	Update	Basis
Phenmedipham	13684-63-4	1.5 mg/m3 (TWA)		OES BCS*
Desmedipham	13684-56-5	1.2 mg/m3 (TWA)		OES BCS*
Ethofumesate	26225-79-6	10 mg/m3 (TWA)		OES BCS*
Soybean oil	8001-22-7	3 mg/m3 (TWA)	11 2020	NZ OEL
(Respirable dust.)				
Soybean oil	8001-22-7	10 mg/m3 (TWA)	11 2020	NZ OEL
(Inhalable dust.)				
Soybean oil	8001-22-7	10 mg/m3 (TWA)	06 2016	NZ OEL
(Mist.)				
1,2-Propanediol	57-55-6	10 mg/m3 (TWA)	07 2011	NZ OEL
(Particulate.)		, ,		
1,2-Propanediol	57-55-6	474 mg/m3/150 ppm (TWA)	07 2011	NZ OEL
(Vapor and particulates.)		·		

<sup>\*</sup>OES BCS: Internal Bayer AG, Crop Science Division "Occupational Exposure Standard"

#### 8.2 Exposure controls

#### Personal protective equipment

In normal use and handling conditions please refer to the label and/or leaflet. In all other cases the following recommendations would apply.

**Respiratory protection** Respiratory protection is not required under anticipated

circumstances of exposure.

Respiratory protection should only be used to control residual risk of short duration activities, when all reasonably practicable steps have been taken to reduce exposure at source e.g. containment and/or local extract ventilation. Always follow respirator manufacturer's

instructions regarding wearing and maintenance.

**Hand protection** Please observe the instructions regarding permeability and

breakthrough time which are provided by the supplier of the gloves. Also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion, and the

contact time.

Wash gloves when contaminated. Dispose of when contaminated inside, when perforated or when contamination on the outside cannot be removed. Wash hands frequently and always before eating,



6/13

## **BETANAL QUATTRO**

 Version 2 / NZ
 Revision Date: 29.07.2022

 102000000613
 Print Date: 29.07.2022

drinking, smoking or using the toilet.

Material Nitrile rubber
Rate of permeability > 480 min
Glove thickness > 0.4 mm
Protective index Class 6

Directive Protective gloves complying with EN

374.

**Eye protection** Wear goggles (conforming to EN166, Field of Use = 5 or equivalent).

**Skin and body protection** Wear standard coveralls and Category 3 Type 4 suit.

If there is a risk of significant exposure, consider a higher protective

type suit.

Wear two layers of clothing wherever possible. Polyester/cotton or cotton overalls should be worn under chemical protection suit and

should be professionally laundered frequently.

If chemical protection suit is splashed, sprayed or significantly contaminated, decontaminate as far as possible, then carefully

remove and dispose of as advised by manufacturer.

**General protective measures** If product is handled while not enclosed, and if contact may occur:

Complete suit protecting against chemicals

#### SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

## 9.1 Information on basic physical and chemical properties

Form suspension

Colour white to light beige

**Odour** aromatic

Odour Threshold No data available

**pH** 4.0 - 7.0 (10 %) (23 °C) (deionized water)

Melting point/rangeNo data availableBoiling PointNo data available

Flash point > 100 °C

No flash point - Determination conducted up to the boiling point.

Flammability No data available

Auto-ignition temperature No data available

Ignition temperature 495 °C

Minimum ignition energy No data available
Self-accelarating No data available

decomposition temperature

(SADT)

Upper explosion limitNo data availableLower explosion limitNo data availableVapour pressureNo data available



7/13

## **BETANAL QUATTRO**

 Version 2 / NZ
 Revision Date: 29.07.2022

 102000000613
 Print Date: 29.07.2022

Evaporation rateNo data availableRelative vapour densityNo data availableRelative densityNo data available

**Density** ca. 1.09 g/cm³ (20 °C)

Partition coefficient: n-

octanol/water

Water solubility

Phenmedipham: log Pow: 3.59

Desmedipham: log Pow: 3.39 Ethofumesate: log Pow: 2.7 (25 °C)

Metamitron: log Pow: 0.86

dispersible

Viscosity, dynamic 150 - 350 mPa.s (20 °C)

Velocity gradient 20 /s 50 - 160 mPa.s (20 °C) Velocity gradient 100 /s

Viscosity, kinematic No data available

**Surface tension** ca. 39 mN/m

Determined as a 0,1% solution in distilled water (1 g/l).

**9.2 Other information** Further safety related physical-chemical data are not known.

#### **SECTION 10: STABILITY AND REACTIVITY**

**10.1 Reactivity** Stable under normal conditions.

**10.2 Chemical stability** Stable under recommended storage conditions.

**10.3 Possibility of**No hazardous reactions when stored and handled according to prescribed instructions.

**10.4 Conditions to avoid** Extremes of temperature and direct sunlight.

**10.5** Incompatible materials Store only in the original container.

10.6 Hazardous

decomposition products

No decomposition products expected under normal conditions of use.

#### **SECTION 11: TOXICOLOGICAL INFORMATION**

11.1 Information on hazard classes as defined in regulation (EC) No 1272/2008

Acute oral toxicity LD50 (Rat) > 2,000 mg/kg



8/13

## **BETANAL QUATTRO**

 Version 2 / NZ
 Revision Date: 29.07.2022

 102000000613
 Print Date: 29.07.2022

Acute inhalation toxicity

During intended and foreseen applications, no respirable aerosol is

formed.

Acute dermal toxicity LD50 (Rat) > 4,000 mg/kg Skin corrosion/irritation No skin irritation (Rabbit)

Serious eye damage/eye

irritation

Slight irritant effect - does not require labelling. (Rabbit)

**Respiratory or skin** Skin: Non-sensitizing. (Guinea pig) **sensitisation** OECD Test Guideline 406, Buehler test

Skin: Sensitising (Mouse)

OECD Test Guideline 429, local lymph node assay (LLNA)

#### Assessment STOT Specific target organ toxicity - single exposure

Phenmedipham: Based on available data, the classification criteria are not met. Desmedipham: Based on available data, the classification criteria are not met. Ethofumesate: Based on available data, the classification criteria are not met. Metamitron: Based on available data, the classification criteria are not met.

#### Assessment STOT Specific target organ toxicity - repeated exposure

Phenmedipham caused haemolytic anaemia, methaemoglobinaemia in animal studies. The observed effects do not appear to be relevant for humans.

Desmedipham caused methaemoglobinaemia, haemolytic anaemia in animal studies. The observed effects do not appear to be relevant for humans.

Ethofumesate did not cause specific target organ toxicity in experimental animal studies.

Metamitron did not cause specific target organ toxicity in experimental animal studies.

#### Assessment mutagenicity

Phenmedipham was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.

Desmedipham was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.

Ethofumesate was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

Metamitron was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

#### Assessment carcinogenicity

Phenmedipham was not carcinogenic in lifetime feeding studies in rats and mice.

Desmedipham was not carcinogenic in lifetime feeding studies in rats and mice.

Ethofumesate was not carcinogenic in lifetime feeding studies in rats and mice.

Metamitron was not carcinogenic in lifetime feeding studies in rats and mice.

#### Assessment toxicity to reproduction

Phenmedipham caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Phenmedipham is related to parental toxicity.

Desmedipham caused a reduced litter size and a reduced pup weight. The reproduction toxicity seen with Desmedipham is related to parental toxicity.

Ethofumesate did not cause reproductive toxicity in a two-generation study in rats.

Metamitron did not cause reproductive toxicity in a two-generation study in rats.

#### Assessment developmental toxicity

Phenmedipham caused developmental toxicity only at dose levels toxic to the dams. Phenmedipham caused a delayed ossification of foetuses. The developmental effects seen with Phenmedipham are



9/13

## **BETANAL QUATTRO**

 Version 2 / NZ
 Revision Date: 29.07.2022

 102000000613
 Print Date: 29.07.2022

related to maternal toxicity.

Desmedipham caused developmental toxicity only at dose levels toxic to the dams. Desmedipham caused a delayed ossification of foetuses, an increased incidence of variations. The developmental effects seen with Desmedipham are related to maternal toxicity.

Ethofumesate did not cause developmental toxicity in rats and rabbits. Metamitron did not cause developmental toxicity in rats and rabbits.

#### **Aspiration hazard**

Based on available data, the classification criteria are not met.

#### 11.2 Information on other hazards

## **Endocrine disrupting properties**

**Assessment** The substance/mixture does not contain components considered to have

endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### **SECTION 12: ECOLOGICAL INFORMATION**

12.1 Toxicity

**Toxicity to fish** LC50 (Oncorhynchus mykiss (rainbow trout)) 35 mg/l

static test; Exposure time: 96 h

Toxicity to aquatic

invertebrates

EC50 (Daphnia magna (Water flea)) 8.2 mg/l static test; Exposure time:

48 h

Chronic toxicity to aquatic

invertebrates

NOEC (Daphnia (water flea)): 0.01 mg/l

Exposure time: 21 d

The value mentioned relates to the active ingredient desmedipham.

Toxicity to aquatic plants IC50 (Desmodesmus subspicatus (green algae)) 8.6 mg/l

static test; Exposure time: 72 h

ErC50 (Myriophyllum spicatum (Eurasian watermilfoil)) = 0.479 mg/l

static test; Exposure time: 14 d

The value mentioned relates to the active ingredient ethofumesate.

NOEC (Myriophyllum spicatum (Eurasian watermilfoil)) = 0.036 mg/l

Growth rate; Exposure time: 14 d

The value mentioned relates to the active ingredient ethofumesate.

EC50 (Myriophyllum spicatum (Eurasian watermilfoil)) = 0.0519 mg/l

Biomass; Exposure time: 7 d

The value mentioned relates to the active ingredient phenmedipham.

EC50 (Myriophyllum spicatum (Eurasian watermilfoil)) = 0.0705 mg/l

Growth rate; Exposure time: 7 d

The value mentioned relates to the active ingredient phenmedipham.

EC10 (Myriophyllum spicatum (Eurasian watermilfoil)) = 0.028 mg/l

Biomass; Exposure time: 14 d

The value mentioned relates to the active ingredient phenmedipham.



10/13

## **BETANAL QUATTRO**

 Version 2 / NZ
 Revision Date: 29.07.2022

 102000000613
 Print Date: 29.07.2022

EC10 (Myriophyllum spicatum (Eurasian watermilfoil)) = 0.0208 mg/l

Growth rate: Exposure time: 14 d

The value mentioned relates to the active ingredient phenmedipham.

#### 12.2 Persistence and degradability

Biodegradability Phenmedipham:

Not rapidly biodegradable

Desmedipham:

Not rapidly biodegradable

Ethofumesate:

Not rapidly biodegradable

Metamitron:

Not rapidly biodegradable

**Koc** Phenmedipham: Koc: 888

Desmedipham: Koc: > 5000 Ethofumesate: Koc: 147 Metamitron: Koc: 86.4

#### 12.3 Bioaccumulative potential

**Bioaccumulation** Phenmedipham: Bioconcentration factor (BCF) 165

Does not bioaccumulate.

Desmedipham: Bioconcentration factor (BCF) 157

Does not bioaccumulate.

Ethofumesate: Bioconcentration factor (BCF) 144

Does not bioaccumulate.

Metamitron:

Does not bioaccumulate.

12.4 Mobility in soil

**Mobility in soil** Phenmedipham: Slightly mobile in soils

Desmedipham: Immobile in soil

Ethofumesate: Moderately mobile in soils Metamitron: Moderately mobile in soils

## 12.5 Results of PBT and vPvB assessment

**PBT and vPvB assessment** Phenmedipham: This substance is not considered to be persistent,

bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

Desmedipham: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

Ethofumesate: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

Metamitron: This substance is not considered to be persistent,

bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

## 12.6 Endocrine disrupting properties

**Assessment** The substance/mixture does not contain components considered to have

endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### 12.7 Other adverse effects



## **BETANAL QUATTRO**

11/13 Version 2/NZ Revision Date: 29.07.2022 102000000613 Print Date: 29.07.2022

Additional ecological

information

No other effects to be mentioned.

#### **SECTION 13: DISPOSAL CONSIDERATIONS**

#### 13.1 Waste treatment methods

**Product** Dispose of this product only by using according to the label, or at an

approved landfill or other approved facility.

Triple rinse containers. Recycle if possible. If allowed under local Contaminated packaging

authority, burn if circumstances, especially wind direction permit, otherwise crush and bury in an approved local authority facility. Do not

use container for any other purpose.

#### **SECTION 14: TRANSPORT INFORMATION**

This transportation information is not intended to convey all specific regulatory information relating to this product. It does not address regulatory variations due to package size or special transportation requirements.

#### ADR/RID/ADN

14.1 UN number 3082

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(PHENMEDIPHAM, DESMEDIPHAM, ETHOFUMESATE,

METAMITRON SOLUTION)

14.3 Transport hazard class(es) 9 14.4 Packaging Group Ш 14.5 Environm. Hazardous Mark YES Hazchem Code 3Z

**IMDG** 

14.1 UN number 3082

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(PHENMEDIPHAM, DESMEDIPHAM, ETHOFUMESATE,

METAMITRON SOLUTION)

14.3 Transport hazard class(es) 9 14.4 Packaging Group Ш 14.5 Marine pollutant YES

IATA

14.1 UN number 3082

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

(PHENMEDIPHAM, DESMEDIPHAM, ETHOFUMESATE,

METAMITRON SOLUTION)

14.3 Transport hazard class(es) 9

14.4 Packaging Group Ш 14.5 Environm. Hazardous Mark YES



12/13

## **BETANAL QUATTRO**

Version 2 / NZ
102000000613

Revision Date: 29.07.2022
Print Date: 29.07.2022

#### 14.6 Special precautions for user

See sections 6 to 8 of this Safety Data Sheet.

#### 14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code

No transport in bulk according to the IBC Code.

#### **SECTION 15: REGULATORY INFORMATION**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

#### **Further information**

HSNO approval-Nr. HSR100882

HSNO Controls See www.epa.govt.nz

ACVM Reg. P8851

ACVM Condition See www.foodsafety.govt.nz

#### **SECTION 16: OTHER INFORMATION**

#### Abbreviations and acronyms

ADN European Agreement concerning the International Carriage of Dangerous Goods by

Inland Waterways

ADR European Agreement concerning the International Carriage of Dangerous Goods by

Road

ATE Acute toxicity estimate

CAS-Nr. Chemical Abstracts Service number

Conc. Concentration

ECx Effective concentration to x %

EINECS European inventory of existing commercial substances

ELINCS European list of notified chemical substances

EN European Standard EU European Union

IATA International Air Transport Association

IBC International Code for the Construction and Equipment of Ships Carrying Dangerous

Chemicals in Bulk (IBC Code)

ICx Inhibition concentration to x %

IMDG International Maritime Dangerous Goods

LCx Lethal concentration to x %

LDx Lethal dose to x %

LOEC/LOEL Lowest observed effect concentration/level

MARPOL: International Convention for the prevention of marine pollution from ships

N.O.S. Not otherwise specified

NOEC/NOEL No observed effect concentration/level

OECD Organization for Economic Co-operation and Development

RID Regulations concerning the International Carriage of Dangerous Goods by Rail

TWA Time weighted average

UN United Nations

WHO World health organisation



## **BETANAL QUATTRO**

Version 2/NZ 102000000613

**13/13**Revision Date: 29.07.2022
Print Date: 29.07.2022

The data given here is based on current knowledge and experience. The purpose of this Safety Data Sheet is to describe products in terms of their safety requirements. The above details do not imply any guarantee concerning composition, properties or performance of the product.

**Reason for Revision:** The following sections have been revised: Section 2: Hazards

Identification. Section 3: Composition / Information on Ingredients. Section 4: First Aid Measures. Section 9: Physical and Chemical

Properties.

Changes since the last version are highlighted in the margin. This version replaces all previous versions.